CoChat

Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials

Open access

The DOI matches its Crossref record, with a small difference in title or year; 49 of the 49 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND OBJECTIVES: Identifying a clinically meaningful change in cognitive test score is essential when using cognition as an outcome in clinical trials. This is especially relevant because clinical trials increasingly feature novel composites of cognitive tests. Our primary objective was to establish minimal clinically important differences (MCIDs) for commonly used cognitive tests, using anchor-based and distribution-based methods, and our secondary objective was to investigate a composite cognitive measure that best predicts a minimal change in the Clinical Dementia Rating-Sum of Boxes (CDR-SB). METHODS: From the Swedish BioFINDER cohort study, we consecutively included cognitively unimpaired (CU) individuals with and without subjective or mild cognitive impairment (MCI). We calculated MCIDs associated with a change of ≥0.5 or ≥1.0 on CDR-SB for Mini-Mental State Examination (MMSE), ADAS-Cog delayed recall 10-word list, Stroop, Letter S Fluency, Animal Fluency, Symbol Digit Modalities Test (SDMT) and Trailmaking Test (TMT) A and B, and triangulated MCIDs for clinical use for CU, MCI, and amyloid-positive CU participants. For investigating cognitive measures that best predict a change in CDR-SB of ≥0.5 or ≥1.0 point, we conducted receiver operating characteristic analyses. RESULTS: Our study included 451 cognitively unimpaired individuals, 90 with subjective cognitive decline and 361 without symptoms of cognitive decline (pooled mean follow-up time 32.4 months, SD 26.8, range 12-96 months), and 292 people with MCI (pooled mean follow-up time 19.2 months, SD 19.0, range 12-72 months). We identified potential triangulated MCIDs (cognitively unimpaired; MCI) on a range of cognitive test outcomes: MMSE -1.5, -1.7; ADAS delayed recall 1.4, 1.1; Stroop 5.5, 9.3; Animal Fluency: -2.8, -2.9; Letter S Fluency -2.9, -1.8; SDMT: -3.5, -3.8; TMT A 11.7, 13.0; and TMT B 24.4, 20.1. For amyloid-positive CU, we found the best predicting composite cognitive measure included gender and changes in ADAS delayed recall, MMSE, SDMT, and TMT B. This produced an AUC of 0.87 (95% CI 0.79-0.94, sensitivity 75%, specificity 88%). DISCUSSION: Our MCIDs may be applied in clinical practice or clinical trials for identifying whether a clinically relevant change has occurred. The composite measure can be useful as a clinically relevant cognitive test outcome in preclinical AD trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000200817

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Changes in Clinical Outcome Scores That Indicate Clinically Meaningful Differences (A) Cognitively unimpaired, (B) Mild Cognitive impairment. For MMSE, Animal Fluency, Letter S and Symbol Digit all mean difference scores are negative (see Table 2). ES = estimates of effect size.
Figure 1 Changes in Clinical Outcome Scores That Indicate Clinically Meaningful Differences (A) Cognitively unimpaired, (B) Mild Cognitive impairment. For MMSE, Animal Fluency, Letter S and Symbol Digit all mean difference scores are negative (see Table 2). ES = estimates of effect size.CC BY · PubMed Central
Figure 2 ROC Curves From Logistic Regression Models Estimating Minimally Clinical Difference in CU, MCI, and Amyloid positive CU groups. (A) CU group (N=451). (B) MCI group (N=292). (C) Amyloid positive CU group (N=116). Performance of the best model (defined as lowest AIC including predictors with p < 0.1) and individual tests are shown in receiver operating curves (ROC). Further results are presented in eTables 3-6. Outcomes in A and C are a clinical change in Clinical Dementia Rating Sum of Boxes (CDR-SB) ≥0.5 and in C a clinical change in CDR-SB ≥1 point.
Figure 2 ROC Curves From Logistic Regression Models Estimating Minimally Clinical Difference in CU, MCI, and Amyloid positive CU groups. (A) CU group (N=451). (B) MCI group (N=292). (C) Amyloid positive CU group (N=116). Performance of the best model (defined as lowest AIC including predictors with p < 0.1) and individual tests are shown in receiver operating curves (ROC). Further results are presented in eTables 3-6. Outcomes in A and C are a clinical change in Clinical Dementia Rating Sum of Boxes (CDR-SB) ≥0.5 and in C a clinical change in CDR-SB ≥1 point.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 83

Metadata

Authors
Borland, E., Edgar, C., Stomrud, E., Cullen, N., Hansson, O., & Palmqvist, S.
Affiliations
Lund University (SE)
Corresponding author
Borland, Emma
Venue
Neurology
Published
2022-09-13
Volume
99
Issue
11
Pages
e1142-e1153
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W4285495175
Cited by
83
References
44
Citations by year
2026: 20 · 2025: 27 · 2024: 21 · 2023: 14 · 2022: 1
FWCI
10.25
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Neurology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • Australian Government
  • Lunds Universitet
  • Knut och Alice Wallenbergs Stiftelse (2017‐0383)
  • Vetenskapsrådet (2016-00906, FO2021-0293, 2018-, 2018-02052, 2017-00383)
  • Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (2020-O000028, 2020-0314)
  • Skånes universitetssjukhus (2020-O000028)
  • Marcus och Amalia Wallenbergs minnesfond (2015.0125)
  • Parkinsonfonden (1280/20)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
  • Social Sciences › Psychology › Applied Psychology › Psychological Testing and Assessment
Keywords
minimal clinically important difference, cognitive outcome measures, mild cognitive impairment, subjective cognitive decline, prodromal Alzheimer's disease, CDR-SB, Mini-Mental State Examination, Symbol Digit Modalities Test, Trail Making Test, Stroop task, cognitive decline prediction
MeSH terms
Alzheimer Disease, Cognition, Humans, Neuropsychological Tests, Cohort Studies, Cognitive Dysfunction, Prodromal Symptoms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials. https://app.cochat.ai/papers/10.1212/wnl.0000000000200817
The paper
Borland, E., Edgar, C., Stomrud, E., Cullen, N., Hansson, O., & Palmqvist, S. (2022). Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials. Neurology. https://doi.org/10.1212/wnl.0000000000200817

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.